| Title of Invention | CHIMERIC MONOCLONAL ANTIBODY |
|---|---|
| Abstract | The present invention relates to a chimeric monoclonal antibody derived from the murine anti-idiotypic monoclonal antibody 1E10 that recognizes murine MAb P3 produced by the hybridoma cell lie with deposit number ECACC 97112901, wherein the hypervariable domains of its heavy and light chains comprise the following sequences: |
| Full Text | Statement of Invention An embodiment of the present invention relates to a Chimeric monoclonal antibody derived from the murine anti-idiotypic monoclonal antibody 1E10 that recognizes murine MAb P3 and produced by the hybridoma cell lie with deposit number ECACC 97112901, wherein the constant region of the heavy chain comprises the amino acid sequence of gamma-1 chain and the constant region of the light chain comprises the amino acid sequence of a kappa chain, both derived from the human immunoglobulins and wherein the hypervariable domains of its heavy and light chains comprise the following sequences: (Sequance Removed) wherein the framework regions [FRs] of its heavy and light chains comprise the following sequences: (Sequance Removed) We Claim: 1. A Chimeric monoclonal antibody derived from the murine anti-idiotypic monoclonal antibody 1E10 that recognizes murine MAb P3 and produced by the hybridoma cell lie with deposit number ECACC 97112901, wherein the constant region of the heavy chain comprises the amino acid sequence of gamma-1 chain and the constant region of the light chain comprises the amino acid sequence of a kappa chain, both derived from the human immunoglobulins and wherein the hypervariable domains of its heavy and light chains comprise the following sequences: (Sequance Removed) wherein the framework regions [FRs] of its heavy and light chains comprise the following sequences: (Sequance Removed) 2. A monoclonal antibody as claimed in claim 1, wherein for is humanization and preserving the binding properties to the antigen, the variable region of the antibody includes the following substitutions: (Sequance Removed) Position 87 (83 according to Kabat's numbering): Thr by Arg 3. A pharmaceutical composition as and when prepared by any of the monoclonal antibodies as claimed in claims 1 or 2. 4. A Chimeric monoclonal antibody as claimed in claims 1 or 2 for the manufacture of a medicament useful for the treatment of malignant tumors of beast and melanoma, their metastases and relapses. 5. Use of the monoclonal antibody as claimed in any of the claims 1 or 2 for the "in vivo" localization and identification of malignant tumors of breast and melanomas, their metastases and relapses. 6. A Chimeric monoclonal antibody, a pharmaceutical composition and its use substantially as herein described with reference to accompanying drawing and as illustrated in the foregoing examples. |
|---|
5730-DELNP-2005-Abstract-(17-06-2011).pdf
5730-delnp-2005-Claims-(06-09-2012).pdf
5730-DELNP-2005-Claims-(17-06-2011).pdf
5730-delnp-2005-Correspondence Others-(06-09-2012).pdf
5730-DELNP-2005-Correspondence Others-(17-06-2011).pdf
5730-delnp-2005-correspondence-others-(15-11-2010).pdf
5730-DELNP-2005-Correspondence-Others-(22-11-2010).pdf
5730-delnp-2005-correspondence-others.pdf
5730-DELNP-2005-Form-3-(17-06-2011).pdf
5730-DELNP-2005-Petition-137-(17-06-2011).pdf
| Patent Number | 255073 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 5730/DELNP/2005 | |||||||||||||||
| PG Journal Number | 04/2013 | |||||||||||||||
| Publication Date | 25-Jan-2013 | |||||||||||||||
| Grant Date | 21-Jan-2013 | |||||||||||||||
| Date of Filing | 09-Dec-2005 | |||||||||||||||
| Name of Patentee | CENTRO DE IMMUNOLOGIA MOLECULAR | |||||||||||||||
| Applicant Address | CALLE 216 Y 15, ATABEY, PLAYA, CIUDAD DE LA HABANA 12100, CUBA | |||||||||||||||
Inventors:
|
||||||||||||||||
| PCT International Classification Number | C07K 16/30 | |||||||||||||||
| PCT International Application Number | PCT/CU2002/00003 | |||||||||||||||
| PCT International Filing date | 2002-04-08 | |||||||||||||||
PCT Conventions:
|
||||||||||||||||